HACKENSACK, N.J. and PETACH TIKVAH, Israel, Aug. 13, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the second quarter ended June 30, 2015.

"We continue to advance BrainStorm's lead program, NurOwn®, for the treatment of amyotrophic lateral sclerosis," stated Dr. Tony Fiorino, BrainStorm's CEO. "We announced earlier this week the completion of patient enrollment in our randomized, double-blind, placebo-controlled U.S. phase 2 trial. We are also completing preparations for our first multi-dose clinical trial, for which we will be producing three NurOwn® doses from a single bone marrow aspiration.  We also continue to explore the development of NurOwn® in other clinical and preclinical areas."

"Furthermore," continued Dr. Fiorino, "our strong cash position of approximately $20 million provides more than adequate resources to complete the U.S. phase 2 clinical trial in 2016, to run our planned multi-dose study, and to pursue these additional research and development activities, as well as several important manufacturing initiatives."

Second Quarter 2015 and Recent Highlights

• Completed of enrollment in our randomized, double-blind, placebo controlled, multicenter Phase 2 US trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
• Presented phase 2a results and new analyses of pooled NurOwn® phase 1/2 and phase 2a clinical data at the American Academy of Neurology and International Society for Cellular Therapy annual meetings.
• Validated manufacturing improvements including cryopreservation, extended stability and a shortened production time.
• Appointed Yoram Bibring, who brings more than 25 years of financial leadership in the healthcare and technology industries, as Chief Financial Officer.
• BrainStorm shares added to the Russell Microcap® Index.

Financial Results for the Second Quarter Ended June 30, 2015

• Research and development expenses for the three months ended June 30, 2015 were $1,375,000, compared to $1,245,000 in the first quarter of 2015 and $877,000 in the second quarter of 2014.
• General and administrative expenses for the three months ended June 30, 2015 were approximately $988,000, compared to $960,000 in the first quarter of 2015 and $417,000 in the second quarter of 2014.
• Loss from operations the three months ended on June 30, 2015 was ($2,363,000) compared to ($2,205,000), in the first quarter of 2015 and ($1,294,000) in the second quarter of 2014. 
• Loss from operations for the three months ended on June 30, 2015 reflected stock based compensation expenses of $321,000 compared to $347,000 in the first quarter of 2015 and $176,000 in the second quarter of 2014.   
• Net loss for the three months ended on June 30, 2015 was ($2,265,000), or ($0.12) per share, compared to a net loss of ($2,236,000), or ($0.12) per share in the first quarter of 2015 and ($1,984,000), or ($0.16) per share in the second quarter of 2014.
• The Company had cash, cash equivalents, and short-term deposits of approximately $19.7 million, compared to $8.5 million at December 31, 2014.

Conference Call & Webcast

About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 50 patients with ALS in clinical trials conducted in Israel and the United States, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at www.brainstorm-cell.com.

Safe Harbor Statement
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements.  The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.  These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements.  These forward-looking statements are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Logo - http://photos.prnewswire.com/prnh/20141006/150511

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/brainstorm-cell-therapeutics-reports-second-quarter-2015-financial-results-and-provides-corporate-update-300128081.html

SOURCE BrainStorm Cell Therapeutics Inc.